Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters
The buttoned down execs at Roche don’t traditionally spend much time mourning dead programs or fatal deals. But its brief summary of the pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
